141 related articles for article (PubMed ID: 38799180)
1. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
Karlowsky JA; Lob SH; Siddiqui F; Polis T; Vallejo JL; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae077. PubMed ID: 38799180
[TBL] [Abstract][Full Text] [Related]
2. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and
Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2023 Aug; 5(4):dlad098. PubMed ID: 37577157
[TBL] [Abstract][Full Text] [Related]
3. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
4. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
Karlowsky JA; Lob SH; Bauer KA; Esterly J; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad152. PubMed ID: 38222461
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Karlowsky JA; Lob SH; Khan TK; Chen WT; Woo PCY; Seto WH; Ip M; Leung SWM; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2023 Jun; 33():260-266. PubMed ID: 37086892
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21.
Karlowsky JA; Wise MG; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad149. PubMed ID: 38161963
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
[No Abstract] [Full Text] [Related]
9. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
Eur J Clin Microbiol Infect Dis; 2024 May; ():. PubMed ID: 38775873
[TBL] [Abstract][Full Text] [Related]
10. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility profile and β-lactamase content of global
Karlowsky JA; Lob SH; Estabrook MA; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2023 Jun; 5(3):dlad080. PubMed ID: 37388237
[TBL] [Abstract][Full Text] [Related]
12. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á
Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
[TBL] [Abstract][Full Text] [Related]
18.
Karlowsky JA; Lob SH; Akrich B; DeRyke CA; Siddiqui F; Young K; Motyl MR; Hawser SP; Sahm DF
JAC Antimicrob Resist; 2023 Feb; 5(1):dlad003. PubMed ID: 36694850
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
20. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
Beirão EM; Rodrigues SDS; Andrade TK; Serra FB; Paula MDN; Polis TJB; Gales AC
Braz J Infect Dis; 2020; 24(4):310-321. PubMed ID: 32663440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
